hypertension - strategy - non diabetic patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>hypertension</strong> - strategy </a> - non diabetic patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> MDRD, 1994 </a> <br> </td> <td> low target blood pressure (mean arterial pressure < 92 mm Hg)<br>  <i>versus</i> <br> usual target blood pressure (mean arterial pressure < 107 mm Hg) </td> <td> patients with predominantly nondiabetic kidney disease and a glomerular filtration rate of 13 to 55 mL/min per 1.73 m2 </td> <td> follow-up 2.2 y<br> n=840/0<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> HOT, 1994 </a> <br> </td> <td> less or equal than 85 mmHg, or less or equal than 80 mmHg<br>  <i>versus</i> <br> less or equal than 90 mmHg </td> <td> patients with diastolic blood pressure between 100 mmHg and 115 mmHg </td> <td> follow-up 3.8 y<br> n=12526/6264<br> Factorial plan<br> open <br> 26 countries </td> </tr> <tr> <td> <a href="index.html"> REIN-2, 2005 </a> <br> </td> <td> intensified (systolic/diastolic <130/80 mm Hg) blood-pressure control<br>  <i>versus</i> <br> conventional (diastolic <90 mm Hg) blood-pressure control </td> <td> patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril </td> <td> follow-up 36 months<br> n=169/169<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Toto, 1995 </a> <br> </td> <td> strict blood pressure control (DBP 65 to 80 mm Hg)<br>  <i>versus</i> <br> usual blood pressure control (DBP 85 to 95 mm Hg) </td> <td> non-diabetic patients (age 25 to 73) with long-standing hypertension (DBP > or = 95 mm Hg), chronic renal insufficiency (GFR < or = 70 m/min/1.73 m2) and a normal urine sediment </td> <td> follow-up <br> n=42/35<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Cardio-Sis, 2009 </a> <br> NCT00421863 </td> <td> tighter control of systolic BP with a goal of <130 mm Hg<br>  <i>versus</i> <br> usual control, with a goal of <140 mm Hg </td> <td> nondiabetic patients with hypertension and with SBP of 150 mm Hg or higher confirmed at two different times </td> <td> follow-up 2 years<br> n=558/553<br> Parallel groups<br> open <br> Italy </td> </tr> </table> <h2>References</h2> <p> <b>MDRD, 1994 : </b> Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker GThe effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. <i>N Engl J Med 1994;330:877-84</i> [PMID 8114857] </p> <p> <b>MDRD, 1994 : </b> Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar CAchievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. <i>Hypertension 1997;29:641-50</i> [PMID 9040451] </p> <p> <b>MDRD, 1994 : </b> Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JLBlood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. <i>Ann Intern Med 1995;123:754-62</i> [PMID 7574193] </p> <p> <b>MDRD, 1994 : </b> Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey ASThe effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. <i>Ann Intern Med 2005;142:342-51</i> [PMID 15738453] </p> <p> <b>HOT, 1994 : </b> Hansson L, Zanchetti A, Carruthers SG, Dahl�f B, Elmfeldt D, Julius S, M�nard J, Rahn KH, Wedel H, Westerling SEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. <i>Lancet 1998;351:1755-62</i> [PMID 9635947] </p> <p> <b>HOT, 1994 : </b> Hansson L, Zanchetti AThe Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. <i>Blood Press 1997;6:313-7</i> [PMID 9360003] </p> <p> <b>HOT, 1994 : </b> Hansson L, Zanchetti AThe Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. <i>Blood Press 1994;3:322-7</i> [PMID 7866597] </p> <p> <b>HOT, 1994 : </b> Zanchetti A, Hansson L, Dahl�f B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel HEffects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. <i>J Hypertens 2001;19:1149-59</i> [PMID 11403365] </p> <p> <b>REIN-2, 2005 : </b> Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi GBlood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet 2005;365:939-46</i> [PMID 15766995] 10.1016/S0140-6736(05)71082-5 </p> <p> <b>Toto, 1995 : </b> Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA"Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. <i>Kidney Int 1995;48:851-9</i> [PMID 7474675] </p> <p> <b>Cardio-Sis, 2009 : </b> Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi GUsual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet 2009;374:525-33</i> [PMID 19683638] </p>